Therapeutic Potential of Glutamine Pathway in Lung Cancer.

Front Oncol · 2021 · PMC8873175 · PMID 35223460

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Both Gln and glutamate showed a decreasing trend in cisplatin-resistant lung cancer cells, while Gln was one of the most significantly altered metabolites in cisplatin-treated A549 xenograft mice, suggesting that Gln metabolism makes a great difference in cisplatin chemotherapy resistance in lung cancer ( 74 ).

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.